Follow us: facebook twitter linkedin
Login My ASCCP Search

Journal of Lower Genital Tract Disease (JLGTD)


 

The Journal's mission is to promote excellence in the healthcare of people with diseases of the lower genital tract, to enable healthcare professionals to be well informed, to promote the exchange of ideas, to help advance standards in the conduct and reporting of health research, and to contribute to improving health of people worldwide. 

 

JLGTD Online

 

Now available for iPad®.
See the
 Journal website for details.

 


 


Members

Members can access full-text articles of the Journal, a benefit included with full-membership, through their Journal login.

1. Go to the Journal of Lower Genital Tract Disease main page

2. Login using your Journal credentials (note, in many cases, this is different from your ASCCP login credentials).


Open Access

Please enjoy these recent free articles that are open access and therefore do not require a subscription.

Utility and Reproducibility of the International Federation for Cervical Pathology and Colposcopy Classification of Transformation Zones in Daily Practice: A Multicenter Study of the German Colposcopy Network

Primary Adenocarcinoma of Intestinal Type Arising From a Vaginal Mass: A Case Report

Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis: A Dose-Ranging Study

Evaluation of a Cervicography-Based Program to Ensure Quality of Visual Inspection of the Cervix in HIV-Infected Women in Johannesburg, South Africa


Advertisers

The Journal of Lower Genital Tract Disease is the source for the latest science about benign and malignant conditions of the cervix, vagina, vulva, and anus. Find out more on specifications and review the latest rate card.


Authors

We welcome the submission of your manuscript. You will find JLGTD offers an efficient process and a quick "to print" timeframe. Information for authors.


SCImago Journal & Country Rank
   












   
 
Copyright © 2015. All rights reserved.   Use of this Web site constitutes acceptance of our Terms of Use.